Benchmark Holdings (LON:BMK) interim results presentation to analysts, 18.5.21 by Trond Willliksen, CEO, and Septima Maguire, CFO. Good H1 performance with revenue growth +11% and Adjusted EBITDA +13% reflecting a strong performance in Advanced Nutrition and solid trading in Genetics and Health. Significant progress towards commercialisation of BMK08 and Clean Treat. Positive outlook and trading in line with market expectations, with good revenue visibility for the second half.

Video & Podcast.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here